Ke Lixin, Lu Cuncun, Shen Rui, Lu Tingting, Ma Bin, Hua Yunpeng
Department of Liver Surgery, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Evidence-Based Medicine Center, School of Basic Medical Sciences, Lanzhou University, Lanzhou, China.
Front Pharmacol. 2020 Jun 5;11:842. doi: 10.3389/fphar.2020.00842. eCollection 2020.
BACKGROUND: Drug-induced liver injury (DILI) is a common adverse event, which compromises the safety of numerous drugs, poses a significant risk to patient health, and enhances healthcare expenditures. Many articles have been recently published on DILI related research, though no relevant scientometric study has been published yet. This scientometric study was aimed at comprehensively analyzing the knowledge base and emerging topics on DILI. METHODS: The articles and reviews related to DILI, published from 2010 to 2019 in the Web of Science Core Collection (WoSCC), were retrieved on March 15, 2020, using relevant keywords. Four different scientometric software (HistCite, VOSviewer, CiteSpace, and R-bibliometrix) was used to conduct this scientometric study. RESULTS: A total of 1,995 publications were retrieved (including 1,550 articles and 445 reviews) from 592 academic journals with 56,273 co-cited references in 10 languages by 2,331 institutions from 79 countries/regions. The majority of publications ( = 727, 36.44%) were published in the United States, and the University of North Carolina contributed the most publications ( = 89, 4.46%). The most productive academic journal on DILI was the [ = 79, 3.96%; impact factor (IF) 2018 = 3.564], and was the first co-cited journal ( = 7,383, IF 2018 = 14.971). Fontana RJ and Teschke R may have significant influence on DILI research, with more publications ( = 46; = 39) and co-citations ( = 382; = 945). Definition, incidence rate or clinical characteristics, etiology or pathogenesis (such as the character of the innate immune system, the regulation of cell-death pathways, and susceptible HLA-B5701 genotype), identification of main drugs and causality assessment (criteria and methods) were the knowledge base for DILI research. Exploring the microscopic mechanism (such as the organelle dysfunction and cytotoxicity induced by drugs, and exploration of role of neutrophils in DILI using mouse models) and developed newer approaches to prevent DILI (such as the prospective HLA-B5701 screening and approaches for assessing the potential risk of candidate drugs for DILI) were the recent major topics for DILI research. CONCLUSION: This scientometric study comprehensively reviewed the publications related to DILI during the past decade using quantitative and qualitative methods. This information would provide references for scholars, researching on DILI.
背景:药物性肝损伤(DILI)是一种常见的不良事件,它影响了众多药物的安全性,对患者健康构成重大风险,并增加了医疗费用。最近发表了许多关于DILI相关研究的文章,但尚未发表相关的科学计量学研究。本科学计量学研究旨在全面分析DILI的知识库和新兴主题。 方法:于2020年3月15日,使用相关关键词在Web of Science核心合集(WoSCC)中检索2010年至2019年发表的与DILI相关的文章和综述。使用四种不同的科学计量软件(HistCite、VOSviewer、CiteSpace和R-bibliometrix)进行本科学计量学研究。 结果:共检索到1995篇出版物(包括1550篇文章和445篇综述),来自592种学术期刊,有来自79个国家/地区的2331个机构以10种语言共同引用了56273次参考文献。大多数出版物(n = 727,36.44%)发表在美国,北卡罗来纳大学发表的出版物最多(n = 89,4.46%)。关于DILI的产出最高的学术期刊是《[期刊名称]》[n = 79,3.96%;2018年影响因子(IF)= 3.564],《[期刊名称]》是第一个被共同引用的期刊(n = 7383,2018年IF = 14.971)。丰塔纳·R·J和特施克·R可能对DILI研究有重大影响,发表的文章更多(n = 46;n = 39)且被共同引用次数更多(n = 382;n = 945)。定义、发病率或临床特征、病因或发病机制(如固有免疫系统的特征、细胞死亡途径的调节以及易感的HLA - B5701基因型)、主要药物的识别和因果关系评估(标准和方法)是DILI研究的知识库。探索微观机制(如药物诱导的细胞器功能障碍和细胞毒性,以及使用小鼠模型探索中性粒细胞在DILI中的作用)和开发预防DILI的新方法(如前瞻性HLA - B5701筛查和评估候选药物DILI潜在风险的方法)是DILI研究最近的主要主题。 结论:本科学计量学研究使用定量和定性方法全面回顾了过去十年中与DILI相关的出版物。这些信息将为研究DILI的学者提供参考。
Front Pharmacol. 2020-6-5
J Orthop Surg Res. 2024-9-28
Ann Palliat Med. 2021-5
Front Pharmacol. 2020-3-13
Front Med (Lausanne). 2022-8-10
Front Bioeng Biotechnol. 2024-7-11
Medicine (Baltimore). 2025-8-29
Medicine (Baltimore). 2025-8-29
Front Psychiatry. 2025-8-12
Front Med (Lausanne). 2025-7-29
Medicine (Baltimore). 2025-8-8
Front Med (Lausanne). 2025-7-10
Front Pharmacol. 2020-3-13
Front Public Health. 2019-12-18
Evid Based Complement Alternat Med. 2019-8-1
N Engl J Med. 2019-7-18
Int Immunopharmacol. 2019-4-24
J Transl Med. 2019-2-28
Gastroenterology. 2019-2-8